ConSynance is a clinical-stage virtual biopharmaceutical company focusing on rare diseases in the central nervous system. Our lead asset is CSTI-500, a small molecule first-in-class triple monoamine reuptake inhibitor (TRI) with the potential to benefit patients with Prader-Willi syndrome (PWS) and other related disorders. CSTI-500 was generally safe and well-tolerated in Phase I clinical trials in healthy humans and demonstrated CNS target engagement via PET that predicts efficacy in patients. ConSynance is currently recruiting for a Phase I study in PWS patients (clinicaltrials.gov: NCT05504395) to study the pharmacokinetics and safety in this patient population.
We also have a preclinical candidate, CSTI-200, a small molecule, first-in-class GlyT-1 Inhibitor for the treatment of L-Dopa-induced dyskinesia (LID) in Parkinson’s disease (PD). Based on recent preclinical evidence, GlyT1 inhibition may have a niche in PD not only for the treatment of dyskinesia, but motor fluctuations and PD psychosis. CSTI-200 has a competitive mechanism of binding that provides a “self-regulating” property for potentially better tolerability compared with non-competitive GlyT-1 inhibitors.
In 2021, we reached an asset purchase agreement with Harmony Biosciences for our second drug, (formerly CSTI-100, now renamed HBS-102.) This potential first-in-class MCHR1 antagonist has the potential to treat a variety of neurological disorders. ConSynance currently holds the license of this drug for the Greater China region and Harmony has global commercialization rights outside of Greater China.
Company Details
- Employees
- 3
- Founded
- -
- Address
- 11 University Place, Rensselaer,new York 12144,united States
- Phone
- 518-275-0176
- in****@****nce.com
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- consynance.com
- HQ
- Rensselaer, New York
Consynance Therapeutics, Inc. Questions
Consynance Therapeutics, Inc.'s helpline number is 518-275-0176
Consynance Therapeutics, Inc.'s website is consynance.com
Consynance Therapeutics, Inc.'s LinkedIn profile is https://www.linkedin.com/company/consynance
Consynance Therapeutics, Inc. has
3 employees.
View email and phone details for 3
employees at Consynance Therapeutics, Inc..
Consynance Therapeutics, Inc.'s industry is
Biotechnology Research
Consynance Therapeutics, Inc.'s top competitors are
Sapience Therapeutics, Inc.,
Saniona,
Neurogene Inc.,
Aardvark Therapeutics,
Variational Ai,
Checkpoint Therapeutics Inc,
Lexeo Therapeutics,
Lipidio Pharmaceuticals,
Taconic Biosciences,
Stimvia.
Consynance Therapeutics, Inc.'s support email address is info@consynance.com
Consynance Therapeutics, Inc.'s categories are Biotechnology Research
Consynance Therapeutics, Inc.'s founding year is 2015
